GH1 and neoplasm: The response to SA depends on the presence and/or ratio of somatostatin receptor subtypes (SSTR1–5) on tumor cells; SSTR2, especially, has been positively correlated to the GH-lowering effect of hitherto clinically available analogs [2]–[5].